1. Extra-coronary Calcification and Cardiovascular Events: What Do We Know and Where Are We Heading?

   • Dixitha Anugula
   • Rhanderson Cardoso
   • Miguel Cainzos-Achirica

   Coronary Heart Disease (S. Virani and M. Al Rifai, Section Editors) 30 August 2022 Pages: 755 - 766

   

2. Recent Updates in Hypertriglyceridemia Management for Cardiovascular Disease Prevention

   • Renato Quispe
   • Ty Sweeney
   • Erin D. Michos

   Coronary Heart Disease (S. Virani and M. Al Rifai, Section Editors) 27 July 2022 Pages: 767 - 778

   

3. PCSK9 Monoclonal Antibodies: New Developments and Their Relevance in a Nucleic Acid–Based Therapy Era

   • Ioanna Gouni-Berthold
   • Jonas Schwarz
   • Heiner K. Berthold

   Nonstatin Drugs (L. Tokgozoglu and A.L. Catapano, Section Editors) Open access 28 July 2022 Pages: 779 - 790

   

4. Bempedoic Acid: for Whom and When

   • Massimiliano Ruscica
   • Cesare R. Sirtori
   • Alberto Corsini

   Nonstatin Drugs (L. Tokgozoglu and A.L. Catapano, Section Editors) Open access 28 July 2022 Pages: 791 - 801

   

5. Inclisiran: How Widely and When Should We Use It?

   • Angela Pirillo
   • Alberico Luigi Catapano

   Nonstatin Drugs (L. Tokgozoglu and A.L. Catapano, Section Editors) Open access 25 July 2022 Pages: 803 - 811

   

6. Polypharmacy and Cardiovascular Diseases: Consideration for Older Adults and Women

   • Shreya Patel
   • Manish Kumar
   • Fawaz Alenezi

   Women and Ischemic Heart Disease (J.M. Peña and F. Lin, Section Editors) 21 July 2022 Pages: 813 - 820

   

7. Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond

   • Nabil G. Seidah
   • Damien Garçon

   Genetics and Genomics (R.A. Hegele and L. Brunham, Section Editors) 29 July 2022 Pages: 821 - 830